Skip to main content

Forbion Capital Partners — Portfolio, Page 2

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

124
Companies
$12.0B
Total invested
$96.6M
Avg. check
24
Industries
Biotechnology 18Medical 12Therapeutics 10Health Care 6Pharmaceutical 5Life Science 5+18 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 25–48 of 124
Eeden
April 2025

Eeden converts end-of-life textiles into resources for new textile production.

Fashion · Múnster$20.5M Series A
Granite Bio
April 2025

Granite Bio is a biotechnology business developing novel antibodies to treat inflammatory, autoimmune, and fibrotic disorders.

Biotechnology · Basel$70.0M Series B
AIRNA
April 2025

AIRNA develops RNA editing technologies to create medicines for various diseases.

Biotechnology · Cambridge$155.0M Series B
Genetix Biotherapeutics Inc.
February 2025

Genetix Biotherapeutics develops and delivers approved gene therapies for severe rare genetic diseases like sickle cell.

Biotechnology · SomervillePrivate Equity
Noema Pharma
December 2024

Noema Pharma is a biotech company that develops therapies to address disabling symptoms in conditions of the brain and nervous system.

Biotechnology · Basel$147.2M Series B
New Amsterdam Pharma
December 2024

New Amsterdam is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.

Biotechnology · Naarden$452.6M Post-IPO Equity
Citryll
December 2024

Citryll is a developer of pharmaceutical drugs used to treat autoimmune and other human diseases.

Biopharma · Oss$89.7M Series B
SynOx Therapeutics
October 2024

SynOx Therapeutics is a biotechnology research company that focused on developing the treatment of diffuse tenosynovial giant cell tumors.

Biotechnology · Dublin$92.0M Series B
Purespring Therapeutics
October 2024

Purespring Therapeutics is a gene therapy company that provides treatments for different kidney diseases.

Biotechnology · London$104.5M Series B
LOQUS23 THERAPEUTICS
October 2024

LoQus23 is a DDF-formed company focussing on targeting DNA damage repair pathways to treat Huntington's disease.

Biotechnology · London$46.4M Series A
NOVAMEAT
September 2024

NOVAMEAT develops cutting-edge technological solutions to feed the planet's growing population with plant-based foods.

Alternative Protein · Barcelona$19.3M Series A
Solasta Bio
September 2024

Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.

AgTech · Glasgow$14.0M Series A
CatalYm
July 2024

CatalYm is a biotechnology company developing innovative immunotherapies for cancer patients.

Biotechnology · Planegg$150.0M Series D
Marea Therapeutics
June 2024

Marea is a biotechnology company that develops therapies and medications for the treatment of cardioendocrine illness patients.

Biotechnology · San Francisco$190.0M Series B
Pheon Therapeutics
May 2024

Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that creates ADCs for a variety of difficult-to-treat cancers.

Biotechnology · London$120.0M Series B
Progentos Therapeutics
May 2024

Progentos Therapeutics develops an approach to treat multiple sclerosis that stimulates the body's natural repair mechanisms.

Life Science · Watertown$65.0M Series A
Seamless Therapeutics
April 2024

Seamless Therapeutics is reshaping the gene editing paradigm with a novel approach to restoring health in patients.

Genetics · Dresden$12.6M Seed
Engrail Therapeutics
March 2024

Engrail Therapeutics is a developer of medicines to transform the lives of patients with life-limiting diseases of the nervous system.

Health Care · San Diego$167.0M Series B
Enterprise Therapeutics
January 2024

A UK-based developer of drugs to treat respiratory diseases

Health Care · Falmer$33.1M Series B
Calluna Pharma
January 2024

Calluna Pharma is developing first-in-class therapies designed to defeat chronic inflammation and fibrosis at the source.

Biotechnology · Oslo$81.4M Series A
Kynexis
November 2023

Kynexis is advancing the first potential precision medicine for the treatment of cognitive impairment associated with schizophrenia (CIAS).

Biotechnology · Naarden$61.0M Series A
Aiolos Bio
October 2023

Aiolos Bio is a biotech company developing innovative therapies for respiratory diseases and immune conditions.

Biopharma · San Francisco$245.0M Series A
Rampart Bioscience
October 2023

Rampart Bioscience develops gene medicines to provide long-lasting treatments for a wide range of diseases.

Biopharma · La Jolla$85.0M Series A
Tessellate BIO
October 2023

Tessellate BIO is a biotechnology business in the preclinical stage that focuses on advanced Synthetic Lethality techniques.

Biotechnology · Naarden$8.5M Seed

Where Forbion Capital Partners invests

Biotechnology18
Medical12
Therapeutics10
Health Care6
Pharmaceutical5
Life Science5

About Forbion Capital Partners's portfolio

How many companies has Forbion Capital Partners invested in?▸

Forbion Capital Partners has invested in 124 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Forbion Capital Partners invest in?▸

Forbion Capital Partners's top investment sectors include Biotechnology, Medical, Therapeutics, Health Care, Pharmaceutical. The firm invests across 24 different industry categories.

What is Forbion Capital Partners's largest investment?▸

Among tracked funding rounds, New Amsterdam Pharma received $452.6M in a Post-IPO Equity round. Forbion Capital Partners's total known invested capital is $12.0B.

What is the average investment size for Forbion Capital Partners?▸

Forbion Capital Partners's average investment size is $96.6M across its portfolio of 124 companies.

What are Forbion Capital Partners's most recent investments?▸

Recent Forbion Capital Partners portfolio additions include Eeden, Granite Bio, AIRNA, Genetix Biotherapeutics Inc., Noema Pharma. These companies were founded in 2020 or later.

Reach the founders behind these 124 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →